For US Residents Only

Understanding Metastatic Castration-Resistant Prostate Cancer

PLUVICTO is used for the treatment of PSMA-positive metastatic castration-resistant prostate cancer

Metastatic prostate cancer is a type of prostate cancer that has spread to other parts of your body.
  • Metastatic castration-resistant prostate cancer (mCRPC) is a type of prostate cancer that has spread to other parts of your body and is no longer responding to hormone treatment that lowers testosterone
  • PSMA (prostate-specific membrane antigen) is a biomarker that sits on the outside of prostate cancer cells and is detected by a PSMA positron emission tomography (PET) scan

If your prostate cancer cells have an abundance of PSMA, it means your mCRPC is PSMA positive (PSMA+). PSMA+ cancer cells can be targeted with PLUVICTO™ (lutetium Lu 177 vipivotide tetraxetan).

 

Noncancerous PSMA+ cells and other surrounding cells will also will be impacted.

PSMA is an important biomarker and is found in more than 80% of patients with prostate cancer.

You can find out if your prostate cancer is PSMA+ by having a PSMA PET scan

 

A PSMA PET scan is an imaging test that allows your doctor to check for PSMA+ cancer in your body

 

Ask your doctor about treating your metastatic prostate cancer with PLUVICTO.

Next: How Pluvicto Works >

Advanced Accelerator Applications, a Novartis Company

Use of website is governed by the Terms of Use and Privacy Policy.

© 2022 Advanced Accelerator Applications. All Rights Reserved.

10/22 237065